The medication Sinecod depo is commonly used for the symptomatic relief of dry, irritating coughs that lack physiological purpose or sputum, and is applied across domains where additional symptomatic support is needed. Butamirate citrate is used for the symptomatic treatment of dry, irritant cough of any etiology. It is commonly used across conditions presenting with acute episodes and recurrent manifestations, such as cough following viral infections, persistent chronic cough, and manifestations associated with lower respiratory tract infections.

The sustained-release (depo) form contributes to continuous and extended symptomatic relief. The continuous relief is relevant for the management of the cough associated with whooping cough, and is applied in specialized settings for cough sedation, such as before and after operative procedures. This functional benefit may assist with maintaining comfort during periods of rest by reducing the disruptive effects of night-time coughing. It supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Disruptive Cough

Quick Fact: Relief for Disruptive Cough. The sustained-release formulation is applied when the patient requires temporary, extended assistance in managing persistent, non-productive symptoms that interfere with daily comfort and sleep.

Regulatory References

1. Philippines FDA Verification Portal Drug Insert

Official Eligibility Profile for Butamirate Citrate (Sinecod Depo)

Regulatory agencies define specific populations who must not use this medicine and others for whom use is restricted or conditional, based solely on official labeling information.

Contraindications (Must Not Use)

Population/Condition	Regulatory Status
Known Hypersensitivity or allergy to butamirate citrate or excipients	Contraindicated
First Trimester of Pregnancy	Contraindicated
Concomitant use with Expectorants (mucus-clearing agents)	Contraindicated
Hereditary Fructose Intolerance (if formulation contains sorbitol)	Contraindicated
Children under specified age thresholds (varies by formulation, e.g., under 3 years for some tablets)	Contraindicated

Restricted or Conditional Use

Population/Condition	Regulatory Status
Second and Third Trimesters of Pregnancy	Use with Caution; only if strictly necessary
Breastfeeding Women	Not Recommended (due to lack of data on excretion in breast milk)
Patients with Hepatic (Liver) or Renal (Kidney) Impairment	Use with Caution; requires medical advice

Use of butamirate citrate is restricted to adults and eligible adolescents/children who do not fall into the strictly contraindicated groups, and for whom the conditional use restrictions have been managed under medical advice.

Interactions with other medicines and products

The official interaction profile for Butamirate Citrate is governed by restrictions on co-administration with substances that may create pharmacodynamic conflict or alter the drug's plasma exposure.

---

Interaction scope

Scope Element	Official Regulatory Information
Medicinal product categories with documented interactions	Expectorants (other cough medicines) and Strong enzyme inhibitors.
Specific interacting medicines (if explicitly listed)	Medicines known to have a narrow therapeutic index.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism (with expectorants); Pharmacokinetic risk of increased exposure (with strong enzyme inhibitors).
Timing-based interaction rules (if applicable)	Co-administration with expectorants must be avoided.

---

Interaction classifications (high-level)

Classification Element	Official Regulatory Description
Interaction severity classification	Restriction/Avoidance Required (for all listed combinations).
Regulatory basis	Summary of Product Characteristics (SmPC) and national Prescribing Information documents.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with expectorants must be avoided due to the documented risk of mucus build-up, which can increase the risk of bronchospasm and respiratory tract infections.
• The product should not be used together with strong enzyme inhibitors because of the regulatory-documented risk of increased plasma exposure of Butamirate Citrate.
• The product should not be used together with medicinal products that have a narrow therapeutic index due to the documented risk of altered exposure to these drugs.
• Patients with documented impaired renal or hepatic function may be at a greater risk for adverse effects from drug accumulation, which heightens the risk profile for interactions affecting clearance.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents establish the interaction structure primarily through restrictions on co-administration with products that exhibit antagonistic pharmacodynamic activity or are classified as metabolic inhibitors. This structure defines specific constraints intended to prevent mucus stagnation and mitigate the risk of Butamirate overexposure or altered clearance of sensitive co-administered drugs. No official interaction with food, alcohol, or herbal products is specifically documented.

Butamirate exerts its effect through a dual mechanism that acts both centrally and peripherally to modulate the respiratory system.

Modulating the Central Cough Reflex

This mechanism focuses on the drug's action within the medulla oblongata (brainstem), the coordinating center for the cough reflex. The active molecule and its metabolites modulate neural activity in this region, potentially by engaging the Sigma-1 Receptor (sigma1R). This leads to an elevation of the threshold required for a cough to be triggered, resulting in a physiological modification of the reflex arc.

Dual Action on Airway Muscle Tone and Irritation

This domain covers the drug's complementary action on the tissues outside the brain. The molecule induces a spasmolytic (muscle-relaxing) effect on the bronchial smooth muscle cells, which alters airflow resistance within the respiratory tract. This peripheral action, combined with a dampening of irritation signaling from the respiratory mucosa, influences the contractile state of the airway system and modifies the transmission of afferent signals to the central cough mechanism.

How to use Sinecod depo: Administration Guidelines

The use of Sinecod depo (Butamirate Citrate 50 mg sustained-release tablets) follows specific dosing and administration instructions, ensuring its standardized application.

---

Administration Scope

Instruction Category	Detail
Route of administration	Oral route.
Dosing schedule	Adults: The standard regimen is 50 mg per dose, taken 2 to 3 times daily. The total maximum daily dose should not exceed 150 mg.
Preparation requirements	The sustained-release tablet must be swallowed whole. The tablet must not be split, crushed, or chewed, as this compromises the intended release mechanism.
Age-group administration rules	Adolescents over 12 years: The dose is typically limited to 1 to 2 tablets daily (50 mg to 100 mg total daily dose). The tablet form is generally not recommended for children under 12 years.
Special procedural conditions	Doses are administered at 8 to 12 hour intervals to maintain the necessary sustained effect. Use is intended for the symptomatic period and is generally limited to a maximum of 7 days if symptoms persist.

---

Instruction Classifications

Classification	Detail
Administration method type	Oral swallow-whole method.
Frequency pattern	Daily use, typically divided into 2 to 3 doses per day.
Use-context constraints	Concomitant use with expectorants is avoided.

Sinecod depo: Recent Clinical Evidence

Evidence for Symptomatic Profile of Dry, Irritable Cough

The research on butamirate citrate, the active ingredient in Sinecod depo, explored the symptomatic profile of dry, irritative cough. Researchers utilized formal study designs, including Randomized Controlled Trials (RCTs), comparing the active ingredient against both placebo and other antitussive medicines included in the trials. These studies were used in research exploring how symptoms change over time.

The studies included adult patient groups experiencing cough related to various causes, such as post-viral infections or long-term, non-specific cough. Outcomes measured focused on cough frequency and intensity scores. Researchers also monitored patient-reported outcomes, such as how cough disrupted sleep. In these trials, findings describe patterns observed in the studies over defined intervals, and the evidence is most relevant in trials assessing short-term or episodic symptom patterns.

Research on Cough Reflex Sensitivity

Beyond clinical symptom monitoring, specific experimental studies research examined how butamirate citrate influences the body's cough reflex. These controlled, highly specific research scenarios used challenge agents (like capsaicin) to determine the concentration of an irritant needed to trigger a cough. While some older research describes patterns related to the cough reflex threshold, other, more recent, high-quality challenge studies reported that differences between butamirate citrate and placebo were mixed or were not consistently observed.

Long-Term Evidence, Populations, and Limitations

When reviewing the body of evidence, most available clinical trials focus on research exploring short-term symptom changes related to acute cough. Typical follow-up durations were limited (often spanning only five to seven days). Therefore, the long-term effects are not fully established, and there is limited information for long-term outcomes or the durability of observed symptom patterns.

Research was evaluated in patient groups beyond the general adult population, including older adults and those with carcinoma-associated cough. However, the data for certain groups remain insufficient. The overall evidence base contributes to the broader landscape, but evidence quality varies across studies. Key limitations include the predominantly short-term nature of the follow-up durations and the noted inconsistency of findings in some experimental settings. Certainty remains low regarding long-term outcomes, and results apply only to the populations studied.

Common questions about Sinecod depo (FAQ)

Q: Does Sinecod depo interact with common substances like food, alcohol, or herbal products?

Official product information states that the medicine can typically be taken with or without food. Regulatory warnings indicate that concomitant use with alcohol is generally discouraged due to the potential for increased central nervous system effects, such as drowsiness and dizziness, as noted in the product information. No official interaction with specific herbal products is specifically documented in regulatory sources.

Q: What should I do if I miss a dose of my Sinecod depo?

Regulatory documents recommend that if a dose is missed, the patient should continue with the next scheduled dose at the usual time. It is advised not to take a double dose to make up for the forgotten dose, unless the prescribing healthcare provider has given specific instructions to do so.

Q: What should I do if I take too much Sinecod depo (overdose information)?

Symptoms of an accidental overdose may include signs such as drowsiness, dizziness, nausea, vomiting, and low blood pressure. Regulatory documents emphasize the necessity of seeking immediate emergency medical assistance if an overdose is suspected.

Q: Can Sinecod depo be taken for a productive or wet cough?

The medicine is indicated for the symptomatic relief of a dry, non-productive cough, as stated in the official product information. Furthermore, regulatory warnings specify that co-administration with expectorants (medicines for productive cough) must be avoided due to the documented risk of mucus accumulation and potential complications.

Q: Does Butamirate Citrate cause dependence or addiction?

Studies and official information indicate that Butamirate Citrate is classified as a non-narcotic cough suppressant. Official product information notes that, as a non-opioid, non-narcotic agent, it is not associated with the risk of physical dependence or addiction seen with certain older antitussives.

How to Store and Dispose of Sinecod depo?

The storage and disposal of Sinecod depo (Butamirate Citrate sustained-release tablets) must follow official regulatory requirements to maintain product stability and ensure public safety.

---

Required Storage Conditions

The tablets must be stored at a temperature not exceeding 30 C. Stability is protected by storing the medication away from direct light and moisture; therefore, storage environments such as a bathroom or freezer should be avoided. As a safety precaution mandated for all medicines, Sinecod depo must be kept out of the sight and reach of children.

---

Official Disposal Instructions

Expired or unused tablets must be disposed of according to local regulations. The product should not be flushed down the toilet or poured into a drain. If a drug take-back program is unavailable, official guidelines recommend mixing the medicine with an undesirable substance (e.g., used coffee grounds) and sealing it in a bag before placing it in household trash.